Home based Augmented Reality Platform for Efficient Rehabilitation of stroke patients

Descrizione del progetto

Un’innovativa realtà mista aiuta i pazienti colpiti da ictus nel percorso verso la riabilitazione

L’ictus è la causa più comune di disabilità a lungo termine a livello globale e le innovazioni sono fondamentali per migliorare l’accesso a screening, diagnostica e trattamenti efficaci, nonché per seguire il piano d’azione per l’ictus dell’UE. Ogni anno si registrano milioni di vittime di ictus che necessitano di trattamenti individualizzati efficaci, ottenibili grazie all’utilizzo dei prodotti innovativi dell’azienda svedese BRAIN STIMULATION AB. RehAtt® è un metodo basato sulle tecnologie neuroscientifiche più recenti, ora disponibile usando occhiali intelligenti, che può essere impiegato a domicilio dopo le dimissioni per migliorare la funzione, l’indipendenza e la qualità della vita attraverso giochi tridimensionali divertenti, motivanti e stimolanti in realtà mista. Il progetto HARPER, finanziato dall’UE, contribuirà ad aprire la strada all’ingresso di prodotti innovativi sul mercato globale.

Obiettivo

Brain Stimulation AB is a Swedish SME started in 2011 with the aim of exploiting brain plasticity results from research within
a new concept of rehabilitation and diagnosis of cognitive impairments of attention in stroke patients (the Neglect
Syndrome). We address the global challenge of rehabilitating patients with cognitive and upper limb problems from Stroke,
Dementia, Traumatic Brain Injuries, Parkinson and other degenerative brain diseases. Cognitive impairments as in the
Neglect Syndrome is not discovered nor treated in suitable time and the normal hospital stay is too short to rehabilitate the
patients properly. Our innovation meets the need of early detection and diagnosis as well as efficient rehabilitation of
patients in clinics and that can continue in patients’ home environment. If the Neglect Syndrome is discovered and treated
faster and better than today, the wellbeing of patients will increase. The burden and the costs for their care will be
significantly reduced. Around 30% of the 16 Million new stroke patients worldwide per year suffer from the Neglect
Syndrome i.e. there are 5-6 million new patients per year. Our addressable market exceeds 6 Million patients per year as our
ambition is to reach not just the stroke patients with Neglect Syndrome but also Dementia, Traumatic Brain Injuries,
Parkinson and other degenerative brain diseases. The innovation project will lead to a generation of €10,3 Million in turnover
and creating 40 new job positions in a five-year perspective after market-launch as well as creating IP rights from the
outcome of the Project. The goal is to develop, verify and bring our innovation towards global market launch. We will go
from TRL 6 towards TRL 9 during the full innovation project life cycle. There will be sustainable effects in economic, ecologic
and social terms for effective cognitive rehabilitation performed in people’s homes, with therapist support through e-health
solutions, when needed.

Campo scientifico

Programma(i)

Argomento(i)

EIC-SMEInst-2018-2020 - SME instrument

Invito a presentare proposte

H2020-EIC-SMEInst-2018-2020

Vedi altri progetti per questo bando

Bando secondario

H2020-SMEInst-2018-2020-1

Meccanismo di finanziamento

SME-1 - SME instrument phase 1

Coordinatore

BRAIN STIMULATION AB

Contribution nette de l'UE

€ 50 000,00

Indirizzo

Lovoudden 619
913 33 Holmsund
Svezia

PMI

Sì

Regione

Norra Sverige Övre Norrland Västerbottens län

Tipo di attività

Private for-profit entities (excluding Higher or Secondary Education Establishments)

Collegamenti

Contatta l’organizzazione

Partecipazione a programmi di R&I dell'UE

Rete di collaborazione HORIZON

Altri finanziamenti

€ 21 429,00